Palomino Laboratories (PALX) Liabilities and Shareholders Equity (2022 - 2025)

Palomino Laboratories has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $8.4 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 6006.17% year-over-year to $8.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.8 million (up 11949.68% YoY) and the FY2025 annual result came in at $8.4 million, up 6006.17% from the prior year.
• Liabilities and Shareholders Equity climbed to $8.4 million in Q4 2025 per PALX's latest filing, from $8.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $8.4 million in Q4 2025 and troughed at $322.0 in Q2 2024.
• A 4-year average of $1.5 million and a median of $500.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity fell 24.0% in 2023, then surged 2581502.8% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $500.0 in 2022, then dropped by 24.0% to $380.0 in 2023, then soared by 36248.68% to $138125.0 in 2024, then soared by 6006.17% to $8.4 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $8.4 million, $8.3 million, and $1887.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.